OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $24.6667.

A number of analysts have issued reports on KIDS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Canaccord Genuity Group began coverage on OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price target for the company. Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. BTIG Research increased their target price on OrthoPediatrics from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Finally, Needham & Company LLC raised their target price on OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th.

OrthoPediatrics Trading Down 5.1%

NASDAQ KIDS opened at $15.52 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.55 and a quick ratio of 2.65. The stock has a market capitalization of $392.35 million, a P/E ratio of -9.18 and a beta of 1.07. The firm’s 50-day moving average is $17.31 and its two-hundred day moving average is $17.70. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $26.40.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.11. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.70%. The business had revenue of $61.61 million during the quarter, compared to analysts’ expectations of $61.27 million. On average, sell-side analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current year.

Insider Buying and Selling at OrthoPediatrics

In related news, CFO Fred Hite sold 12,993 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $224,129.25. Following the sale, the chief financial officer directly owned 277,477 shares of the company’s stock, valued at $4,786,478.25. This represents a 4.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 8,614 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $148,591.50. Following the sale, the general counsel owned 149,533 shares in the company, valued at approximately $2,579,444.25. This trade represents a 5.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 58,171 shares of company stock valued at $1,003,450. Corporate insiders own 32.70% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after acquiring an additional 1,139 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Caption Management LLC acquired a new position in OrthoPediatrics during the 3rd quarter worth $54,000. BNP Paribas Financial Markets increased its holdings in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the period. Finally, State of Wyoming increased its holdings in OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after purchasing an additional 4,467 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.